JulieCMartinDNP, AOCN, NP

Family Nurse Practitioner • Greenville, SC

Director, Cancer Research

Join to view full profile

Julie C Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Julie Martin's full profile

Already have an account?

Summary

I am the Director of Research for the Cancer Institute at Prisma Health in Greenville, SC. For over 35 years, my nursing career has centered around the care of oncology patients. I received my undergraduate degree from the University of South Carolina, a Master of Science degree from Clemson University and am a Board-Certified Family Nurse Practitioner. I received a Doctor of Nursing Practice degree from Chatham University. My research oversight principally includes our institution’s National Cancer Institute Clinical Oncology Research Program (NCORP), the Phase I Clinical Research Unit and Biorepository Services, the Center for Integrative Oncology and Survivorship (CIOS), Oncology Research related to Nursing and Allied Health, and the Center for Cancer Prevention and Wellness. In my role, I provide overall leadership and direction for the research staff and serves as a mentor in guiding young investigators of the Cancer Institute. In addition, I collaborate with research project leads to assist with study design and implementation, regulatory processes, contracts, and budgets, and serve as a resource for grant writing and extramural funding opportunities.

Education & Training

Chatham UniversityDoctorate, 2014 - 2015
Clemson University Graduate SchoolMasters, 2002
Mary Black School of Nursing, University of South Carolina at SpartanburgB.S., Nursing, 1989
Mary Black School of Nursing, University of South Carolina at SpartanburgA.S., Technical Nursing, 1985

Publications & Presentations

Journal Articles

Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy
Gluck WL, Martin J, Edenfield WJ, Chung KY, Arguello D, Colorectal Cancer, 1/1/2017
Randomized Phase 2 Study of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) versus Erlotinib in Patients with Non-Small Cell Lung Cancer
Stephenson, Joe J., John Nemunaitis, Anil A. Joy, Julie C. Martin, Ying-Ming Jou, Da Zhang, Paul Statkevich, et al, Lung Cancer, 1/1/2014
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
Antoinette R. Tan, Darlene G. Gibbon, Mark N. Stein, Diana Lindquist, Jeffery W. Edenfield, Julie C. Martin, Charles Gregory, A. Benjamin Suttle, Hiroomi Tada, Jeffrey..., Cancer Chemotherapy and Pharmacology, 1/1/2013
A Phase I Trial of PX-12, a Small-molecule Inhibitor of Thioredoxin-1, Administered as a 72-Hour Infusion Every 21 Days in Patients with Advanced Cancers Refractory to...
Ramesh K. Ramanathan, Joe J. Stephenson, Glen J Weiss, Linda A. Pestano, Ann Lowe, Alton Hiscox, Rafael A. Leos, Julie C. Martin, Lynn Kirkpatrick, Donald A. Richards, Investigational New Drugs, 1/1/2012
Phase I Study of the Safety, Pharmacokinetcs (PK), and Pharmacodynamics (PO) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in Combination with Temozolomide...
Alain C. Mita, Monica M. Mita, John Sarantopoulos, Julie C. Martin, Janet D. Kueber, Sharon McGonigle, Mark Matijevic, Bipin Misty, Javier Ferrada, Pallavi Sachdev, Jo..., Molecular Cancer Therapeutics, 1/1/2011
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors
Joe J. Stephenson, Charles Gregory, Howard Burris, Tim Larson, Udit Verma, Allen Cohn, Jeffrey Crawford, Roger B. Cohen, Julie Martin, Peggy Lum, Xinqun Yang, Rafael G..., Clinical Colorectal Cancer, 1/1/2009
Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies
J. J. Stephenson, N. Lewis, J. C. Martin, A. Ho, J. Li, K. Wu, L. Pace, J. P. Eder, G. K. Schwartz, American Society of Clinical Oncology, 1/1/2008
A phase II clinical study of dendritoma vaccination combined with low dose interleukin-2 in advanced melanoma patients
Y. C. Wei, J. J. Stephenson, J. Li, K. E. Burgin, H. Bouton-Verville, S. Jakubchak, L. M. Holmes, K. Meyer, J. Martin, S. D. Trocha, T. E. Wagner, Journal of Clinical Oncology, 1/1/2007
Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study
Wei, YC, Sticca, RP, Li, J, Holmes, LM, Burgin, KE, Jakubchak, S, Bouton-Verville, H, Williamson, J, Meyer, K, Evans, L, Martin, JC, Stephenson, JJ, Trocha, S, Smith, ..., Oncology Reports, 1/1/2007
Join now to see all

Lectures

Bone Complications in Breast Cancer
San Diego, CA - 1/14/2010
The Phase I Clinical Research Unit-The Future of Cancer Therapy
1/1/2005
Cancer Prevention-What You Should Know
1/1/2001
Institutional Review Boards and Informed Consent
1/1/2000
Institutional Review Boards and the Process of Informed Consent
1/1/1999
Join now to see all

Office
900 W Faris Rd
Greenville, SC 29605
Phone+1 864-455-7070

Fax+1 864-454-4669